Until recently, there had not been a new product introduced in the wound care arena that had gone through the Food and Drug Administration (FDA) approval process in several years. The FDA recently announced the approval of the Omnigraft Dermal Regeneration Matrix (Integra LifeSciences) for its new indication in the treatment of diabetic foot ulcers in the outpatient clinical setting.
David G. Armstrong DPM MD PhD | 3,405 reads | 0 comments | 01/01/2016
When we tackle the problem of diabetic foot ulcers, the idea is not just the mortality. The idea is that diabetes is like cancer but we do not tend to treat diabetes like cancer and we should be. We should be communicating and using the same language in terms of morbidity and mortality as we do with cancer. When we look at the data from a new study, the mortality rate is similar to the rate of very aggressive cancer.1
Wayne J. Caputo, DPM, FACFAS, and George J. Fahoury, DPM, FACFAS | 3,401 reads | 0 comments | 02/22/2016
The goal of wound management is to attain cost effective wound closure to reestablish function.1 This is especially true with lower extremity wounds that are debilitating and often lead to a temporary or permanent disability.
Chronic wounds, typically defined as wounds that have not decreased in size by 50 percent after four to six weeks of treatment, are often accompanied by complications including peripheral neuropathy, diabetes, peripheral vascular disease (PVD) and poor patient adherence.1-4
At one point, limb loss due to diabetes occurred every 30 seconds. Recent research has reduced the figure to every 20 seconds.1-3 Eighty-five percent of lower limb amputations follow incidence of a diabetic foot ulcer and most are preventable.4,5
The treatment of chronic diabetic foot ulcers is a challenging endeavor. Fortunately, medical advances continue to provide promising new technologies to aid physicians in healing difficult wounds. The properties and composition of placental membranes make them a very powerful tool in wound care as placental membranes address the unique myriad needs of chronic diabetic foot ulcers (DFUs).